NEW YORK (GenomeWeb News) – MDxHealth today said that it has signed a partnership with a subsidiary of Sumitomo to bring the firm's molecular diagnostics products to the Japanese market.

Liege, Belgium-based MDxHealth said that Sumitomo subsidiary Summit Pharmaceuticals International will market its pharmaco molecular diagnostic epigenetic technologies and products. Specifically, Summit will aim to provide companion diagnostics to pharmaceutical firms in the Japanese market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.